PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers
Alexander Drilon(Memorial Sloan Kettering Cancer Center), Kristoffer Staal Rohrberg(Rigshospitalet), Nathan A. Pennell(Cleveland Clinic), Kadoaki Ohashi(Okayama University Hospital), Nehal J. Lakhani(South Texas Accelerated Research Therapeutics), Marcia S. Brose(Sidney Kimmel Cancer Center), Filippo de Braud(University of Milan), Wallace Akerley(University of Utah), Valentina Boni, Jared Weiss(University of North Carolina at Chapel Hill), Benjamin Besse(Institut Gustave Roussy), Lori J. Wirth(Massachusetts General Hospital), Sichuang Tan(National Cancer Centre Singapore), Lyudmila Bazhenova(University of California San Diego), Herbert H. Loong(Memorial Sloan Kettering Cancer Center), Caroline E. McCoach(Memorial Sloan Kettering Cancer Center), Nir Peled(Shaare Zedek Medical Center), Jyoti D. Patel(Memorial Sloan Kettering Cancer Center), Miyako Satouchi(Memorial Sloan Kettering Cancer Center), Manisha H. Shah(Pakistan Institute of Medical Sciences), Atsushi Horiike(The Cancer Institute Hospital), Todd M. Bauer(Tennessee Oncology), Alexander I. Spira(Virginia Cancer Specialists), Geoffrey R. Oxnard(Foundation Medicine (United States)), Melissa L. Johnson(Tennessee Oncology), Mark E. Burkard(University of Wisconsin–Madison), Karen L. Reckamp(Memorial Sloan Kettering Cancer Center), Marc Matrana(Ochsner Medical Center), D.H. Lee(Asan Medical Center), Takeshi Seto(National Hospital Organization Kyushu Cancer Center), Jacques Médioni, Matomo Nishio(The Cancer Institute Hospital), Byoung Chul Cho(Yonsei University), Vamsidhar Velcheti(Cleveland Clinic), Gerald S. Falchook(The University of Texas MD Anderson Cancer Center), Oliver Gautschi(Université Toulouse III - Paul Sabatier), Christian Rolfo(Icahn School of Medicine at Mount Sinai), Tomohiro Sakamoto(Memorial Sloan Kettering Cancer Center), Ignacio Matos(Vall d'Hebron Institute of Oncology), Haruko Daga(Osaka City General Hospital), Viola W. Zhu(University of California, Irvine), Fabrice Barlési(Hôpital Nord), Yoon Jun Kim(Seoul National University), Lixin Song(Kaiser Permanente Santa Clara Medical Center), Junyi Han(National Cancer Center), Y. Ohe(National Cancer Center), Ryo Toyozawa(National Hospital Organization Kyushu Cancer Center), K. Park(Samsung Medical Center), Hovav Nechushtan(University Medical Center)
Cited by 81
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k